Implementing a Pulmonary Telerehabilitation Program for Young Adults with Post-COVID-19 Conditions: A Pilot Study.

Implementing a Pulmonary Telerehabilitation Program for Young Adults with Post-COVID-19 Conditions: A Pilot Study.

Publication date: Sep 16, 2024

Several studies have shown that pulmonary telerehabilitation (PTR) improves respiratory capacity. However, there is little evidence of its effectiveness in youth with post-COVID-19 conditions (PCC). This study analyzed the effects of a PTR program on young adults with PCC. Sixteen youths were randomly assigned to a control group (CG) or an experimental group (EG), with eight participants each. The EG participated in a PTR program that included twelve remote, asynchronous four-week sessions with diaphragmatic breathing and aerobic exercises. Vital signs (SpO, HR, RR, BP), physical capacity (sit-to-stand test), cardiorespiratory capacity (6-Minute Walk Test), and perceived exertion (Borg scale) were assessed in both groups. Statistical analyses showed a significant decrease in RR and HR (p < 0. 012) and an increase in SpO (p < 0. 042), physical (p < 0. 012), and respiratory (p < 0. 028) capacity. Perceived effort decreased significantly in both groups (CG: p < 0. 006; EG: p < 0. 001) only for physical but not for cardiorespiratory capacity (p < 0. 106). There were no statistical changes registered in BP (p > 0. 05). The PTR program, which includes respiratory and aerobic exercises, is feasible and effective in improving physical and cardiorespiratory capacity in young people with PCC, as well as reducing HR, RR, and dyspnea.

Open Access PDF

Concepts Keywords
Cardiorespiratory aerobic exercises
Healthcare COVID-19
Improving pulmonary rehabilitation
Pilot telerehabilitation
Week young adults

Semantics

Type Source Name
drug DRUGBANK Factor IX Complex (Human)
disease MESH dyspnea
disease MESH COVID 19
disease MESH viral infection
disease MESH chest pain
drug DRUGBANK Coenzyme M
disease MESH infection
disease IDO immune response
disease MESH oxidative damage
disease IDO intervention
disease MESH pulmonary diseases
drug DRUGBANK Oxygen
disease IDO blood
disease MESH dissociation
disease IDO process
disease MESH sequelae
disease IDO symptom
drug DRUGBANK Trestolone
disease MESH chronic conditions
disease MESH long covid
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Sulfasalazine
disease MESH syndrome
drug DRUGBANK D-Alanine
disease MESH heart failure
disease MESH COPD

Original Article

(Visited 3 times, 1 visits today)